International Journal of Radiation Oncology * Biology * Physics
Volume 75, Issue 1 , Pages 10-15 , 1 September 2009

Interval to Testosterone Recovery After Hormonal Therapy for Prostate Cancer and Risk of Death

  • Anthony V. D'Amico, M.D., Ph.D.

      Affiliations

    • Department of Radiation Oncology, Brigham and Women's Hospital and Dana Farber Cancer Institute, Boston, MA
    • Corresponding Author InformationReprint requests to: Anthony V. D'Amico, M.D., Ph.D., Department of Radiation Oncology, Brigham and Women's Hospital, 75 Francis Street, L-2 Level, Boston, MA 02215. Tel: (617) 632-6328; Fax: (617) 632-2165
    • ,
  • Ming-Hui Chen, Ph.D.

      Affiliations

    • Department of Statistics, University of Connecticut, Storrs, CT
    • ,
  • Andrew A. Renshaw, M.D.

      Affiliations

    • Department of Pathology, Brigham and Women's Hospital and Dana Farber Cancer Institute, Boston, MA
    • ,
  • Marian Loffredo, R.N., O.C.N.

      Affiliations

    • Department of Radiation Oncology, Brigham and Women's Hospital and Dana Farber Cancer Institute, Boston, MA
    • ,
  • Philip W. Kantoff, M.D.

      Affiliations

    • Department of Medicine, Brigham and Women's Hospital and Dana Farber Cancer Institute, Boston, MA

Received 3 October 2008 ,Revised 18 October 2008 ,Accepted 30 October 2008.

References 

  1. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression therapy and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomized trial. Lancet. 2002;360:103–108
  2. Horwitz EM, Bae K, Hanks GE, et al. Ten-year follow-up of Radiation Therapy Oncology Group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol. 2008;26:2497–2504
  3. Denham J, Steigler A, Lamb DS, et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Tran-Tasman Radiation Oncology Group 96-01 randomised controlled trial. Lancet Oncol. 2005;6:841–850
  4. D'Amico AV, Chen M, Renshaw AA, et al. Androgen suppression and radiation vs radiation alone for prostate cancer: A randomized trial. JAMA. 2008;299:289–295
  5. D'Amico AV, Renshaw AA, Loffredo M, et al. Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapy. Cancer. 2007;110:1723–1728
  6. Gulley JL, Figg WD, Steinberg SM, et al. A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on randomized phase III clinical trials using limited hormonal therapy. J Urol. 2005;173:1567–1571
  7. Oefelein MG. Serum testosterone-based luteinizing hormone-releasing hormone agonist redosing schedule for chronic androgen ablation: A phase I assessment. Urology. 1999;54:694–699
  8. Kaku H, Saika T, Tsushima T, et al. Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. Prostate. 2006;66:439–444
  9. Bong GW, Clarke HS, Hancock WC, et al. Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing agonist in patients with prostate cancer. Urology. 2008;71:1177–1180
  10. Piccirillo JF, Tierney RM, Costas I, et al. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004;291:2441–2447
  11. Beahrs OH, Henson DE, Hunter RVP American Joint Committee on Cancer. Manual for staging cancer. 4th ed.. Philadelphia: JB Lippincott; 1992;
  12. In:  Agresti A editors. An introduction to categorical data analysis. 2nd ed. New York: John Wiley & Sons; 2002;p. 16–52
  13. In:  Hollander M,  Douglas A,  Wolfee DA editor. Nonparametric statistical methods. 2nd ed. New York: John Wiley & Sons; 1999;p. 189–269
  14. Klein JP, Moeschberger ML. Semiparametric proportional hazards regression with fixed covariates. In:  Klein JP,  Moeschberger ML editor. Survival analysis: techniques for censored and truncated data. 2nd ed. New York: Springer; 2003;p. 243–293
  15. Klein JP, Moeschberger ML. Refinements of the semiparametric proportional hazards model. In:  Klein JP,  Moeschberger ML editor. Survival analysis: techniques for censored and truncated data. 2nd ed. New York: Springer; 2003;p. 295–328
  16. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969–974
  17. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–500
  18. Gaynor JJ, Feuer EJ, Tan CC, et al. On the use of cause-specific failure and conditional failure probabilities: Examples from clinical oncology data. J Am Stat Assoc. 1993;88:400–409
  19. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141–1154
  20. In:  Neter J,  Wassermann W,  Kutner M editor. Simultaneous inferences and other topics in regression analyses-1. In: applied linear regression models. Homewood, IL: Richard D Irwin; 1983;p. 150–153
  21. Bolla M, van Tienhoven G, de Reijke TM, et al. EORTC Radiation Oncology and Genito-Urinary Tract Cancer Groups Concomitant and adjuvant androgen deprivation (ADT) with external beam irradiation (RT) for locally advanced prostate cancer: 6 months versus 3 years ADT—Results of the randomized EORTC phase III trial 22961. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol. 2007;25(Suppl):18S
  22. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;29:238–244
  23. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24:4448–4456
  24. Braga-Basaria M, Dobs AS, Muller DC, et al. Metabolic syndrome in men with prostate cancer undergoing long-tern androgen deprivation therapy. J Clin Oncol. 2006;24:3979–3983
  25. D'Amico AV, Denham JW, Crook J, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol. 2007;25:2420–2425
  26. Camara C, Dall'Oglio MF, Alexana C, et al. High prevalence of metabolic syndrome in patients undergoing long-term hormonal therapy for prostate cancer—A preliminary report. AUA Annual Meeting Proceedings. J Urol. 2007;179(Suppl):401

PII: S0360-3016(08)03908-4

doi: 10.1016/j.ijrobp.2008.10.082

International Journal of Radiation Oncology * Biology * Physics
Volume 75, Issue 1 , Pages 10-15 , 1 September 2009

Article Tools

* Image Usage & Resolution